Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma

PURPOSE: Uterine serous carcinoma (USC) exhibits worse survival rates compared to the endometrioid subtype, and there is currently no effective treatment options for recurrence of this disease after platinum-based chemotherapy. Activation of PIK3CA/AKT/mTOR signaling pathway is a common biological f...

Descripción completa

Detalles Bibliográficos
Autores principales: Burkett, Wesley C., Zhao, Ziyi, Newton, Meredith A., Sun, Wenchuan, Deng, Boer, Secord, Angeles Alvarez, Zhou, Chunxiao, Bae-Jump, Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930841/
https://www.ncbi.nlm.nih.gov/pubmed/36773034
http://dx.doi.org/10.1080/07853890.2023.2177883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930841/
https://www.ncbi.nlm.nih.gov/pubmed/36773034
http://dx.doi.org/10.1080/07853890.2023.2177883

Ejemplares similares